We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Prophylactic Antibiotic Regimens in Tumor Surgery (PARITY) (PARITY)

This study is currently recruiting participants.
Verified May 2017 by Michelle Ghert, McMaster University
Sponsor:
ClinicalTrials.gov Identifier:
NCT01479283
First Posted: November 24, 2011
Last Update Posted: May 25, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Collaborators:
Orthopedic Research and Education Foundation
The Physicians' Services Incorporated Foundation
Canadian Cancer Society Research Institute (CCSRI)
Canadian Institutes of Health Research (CIHR)
Information provided by (Responsible Party):
Michelle Ghert, McMaster University
  Purpose
The Prophylactic Antibiotic Regimens in Tumor Surgery (PARITY) trial is the first ever international multi-center randomized controlled trial in bone cancer surgery. In order to avoid amputation for bone cancer in the leg, complex limb-saving operations are performed. However, infections with devastating complications following surgery are common. Surgeons from across the world will randomize patients to receive either short- or long-duration antibiotic regimens after surgery with the goal of identifying the best regimen to reduce these infections.

Condition Intervention Phase
Infection Bone Neoplasms Drug: 24-Hour Prophylactic Cefazolin* Antibiotic Regimen Drug: 5-Days Prophylactic Cefazolin* Antibiotic Regimen Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Prophylactic Antibiotic Regimens in Tumor Surgery (PARITY): A Multi-Center International Randomized Controlled Trial Comparing Alternative Antibiotic Regimens in Patients Undergoing Tumor Resections With Endoprosthetic Replacements

Resource links provided by NLM:


Further study details as provided by Michelle Ghert, McMaster University:

Primary Outcome Measures:
  • Surgical Site Infections [ Time Frame: 1 year ]
    the development of a surgical site infection according to the criteria established by the Center for Disease Control (CDC)


Secondary Outcome Measures:
  • Functional Outcome and Quality of Life [ Time Frame: 1 year ]
    as measured by the Musculoskeletal Tumor Society (MSTS) functional score (1987 and 1993 versions) and the Toronto Extremity Salvage Score (TESS) questionnaires

  • Antibiotic-Related Complications [ Time Frame: 1 year ]
    examples of antibiotic-related complications include gastrointestinal infections, fungal infections, etc.

  • Rate of Re-Operation [ Time Frame: 1 year ]
    re-operation may be required if patients develop a surgical site infection

  • Oncologic Recurrence and/or Metastases [ Time Frame: 1 year ]
  • Mortality [ Time Frame: 1 year ]

Estimated Enrollment: 600
Study Start Date: January 2013
Estimated Study Completion Date: December 2020
Estimated Primary Completion Date: December 2020 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Short-Arm Antibiotic Regimen

Intervention: 24-Hour Prophylactic Cefazolin* Antibiotic Regimen

*or another cephalosporin with equivalent gram-positive coverage in centers where cefazolin is not routinely used or not approved for use

Drug: 24-Hour Prophylactic Cefazolin* Antibiotic Regimen

Pre-Operative Antibiotic Regimen: Patients will receive 2g (or a weight-based dose based on 100mg/kg/day with a maximum single dose of 2g if < 18 years old) of IV cefazolin within 60 minutes prior to the procedure. No other pre-operative antibiotics will be administered.

Intra-Operative Antibiotic Regimen: Patients will receive 2g (or a weight-based dose based on 100mg/kg/day with a maximum single dose of 2g if < 18 years old) of IV cefazolin every 3-4 hours. No other intra-operative antibiotics will be administered.

Post-Operative Antibiotic Regimen: Patients will receive 2g (or a weight-based dose based on 100mg/kg/day with a maximum single dose of 2g if < 18 years old) of IV cefazolin every 8 hours for 24 hours followed by IV saline for 4 days. No other post-operative antibiotics will be administered.

Other Name: ANCEF ®
Experimental: Long-Arm Antibiotic Regimen

Intervention: 5-Days Prophylactic Cefazolin* Antibiotic Regimen

*or another cephalosporin with equivalent gram-positive coverage in centers where cefazolin is not routinely used or not approved for use

Drug: 5-Days Prophylactic Cefazolin* Antibiotic Regimen

Pre-Operative Antibiotic Regimen: Patients will receive 2g (or a weight-based dose based on 100mg/kg/day with a maximum single dose of 2g if < 18 years old) of IV cefazolin within 60 minutes prior to the procedure. No other pre-operative antibiotics will be administered.

Intra-Operative Antibiotic Regimen: Patients will receive 2g (or a weight-based dose based on 100mg/kg/day with a maximum single dose of 2g if < 18 years old) of IV cefazolin every 3-4 hours. No other intra-operative antibiotics will be administered.

Post-Operative Antibiotic Regimen: Patients will receive 2g (or a weight-based dose based on 100mg/kg/day with a maximum single dose of 2g if < 18 years old) of IV cefazolin every 8 hours for 5 days. No other post-operative antibiotics will be administered.

Other Name: ANCEF ®

Detailed Description:
Long-bone sarcomas were historically managed with amputation. In the current era of osteosarcoma management, amputations are generally avoided by complex surgeries in which the malignancy is removed and the limb is reconstructed with advanced surgical techniques. This process of limb salvage is possible with improvements in chemotherapeutic regimens, advanced imaging techniques and surgical innovations such as modular metallic implants. However, the risk for surgical complications is high due to the complexity of the surgeries themselves. The most common and devastating complication is a surgical site infection. Background work and data from our pilot study indicates that infection rates approach 15%. Multiple surgical attempts at eradication of the infection fail in 50% of these cases, resulting in amputation. Published guidelines for post-operative antibiotic prophylaxis following many standard and less complex elective surgical procedures dictate that prophylactic antibiotics be discontinued after 24 hours. However, the most effective duration of treatment in sarcoma surgery has not previously been examined. Given the limitations of the evidence, it has not been possible for orthopaedic oncologists to draw firm conclusions and, therefore, clinical practice is highly varied, particularly with respect to antibiotic duration. Our international, multi-center randomized controlled trial will determine whether a 5-day regimen of post-operative prophylactic antibiotics in comparison to a standard 24-hour regimen decreases the rate of surgical site infections after limb salvage surgery within 1-year follow-up.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   12 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • primary bone malignancies or aggressive benign bone tumors of the femur or tibia, soft-tissue sarcomas which have invaded the femur or tibia, or oligometastatic bone disease of the femur or tibia in a patient expected to live at least one year post-operatively; and
  • treatment by surgical excision and endoprosthetic replacement of the femur or tibia.

Exclusion Criteria:

  • current known Methicillin-resistant Staphylococcus Aureus (MRSA) colonization;
  • current known Vancomycin Resistant Enterococcus (VRE) colonization;
  • documented anaphylaxis or angioedema to penicillin or cefazolin (Ancef);
  • current surgical procedure is a revision surgery for implant failure or infection;
  • prior local infection within the surgical field of the affected limb;
  • current known immunologically-deficient disease conditions (not including recent chemotherapy);
  • known renal insufficiency with estimated creatinine clearance (eGRF) of less than 54 mL/min;
  • reconstruction to include structural allograft;
  • enrolled in a competing study; and
  • weight of less than or equal to 45 kg (for sites using cefuroxime only).
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01479283


Contacts
Contact: Tricia Schneider, B.Sc (905) 527-4322 ext 44983 schnep@mcmaster.ca
Contact: Paula McKay, B.Sc (905) 527-4322 ext 44131 mckayp@mcmaster.ca

  Hide Study Locations
Locations
United States, California
Stanford University Hospital and Clinics Recruiting
Redwood City, California, United States, 94063
Principal Investigator: Raffi Avedian, MD, FACS         
University of California San Francisco Medical Center Recruiting
San Francisco, California, United States, 94118
Principal Investigator: Rosanna Wustrack, MD. FACS         
Sub-Investigator: Richard J. O'Donnell, MD, FACS         
United States, Connecticut
University of Connecticut Health Center Not yet recruiting
Farmington, Connecticut, United States, 06030
Principal Investigator: Adam Lindsay, MD, FACS         
United States, Florida
University of Florida Health Shands Hospital Recruiting
Gainesville, Florida, United States, 32611-2727
Principal Investigator: André Spiguel, MD, FACS         
Sub-Investigator: C. Parker Gibbs, MD, FACS         
Sub-Investigator: Mark Scarborough, MD, FACS         
United States, Georgia
Emory Orthopaedics and Spine Center Terminated
Atlanta, Georgia, United States, 30329
United States, Iowa
Holden Comprehensive Cancer Center Recruiting
Iowa City, Iowa, United States, 52242
Principal Investigator: Benjamin Miller, MD, FACS         
United States, Maryland
University of Maryland Medical Center Recruiting
Baltimore, Maryland, United States, 21201
Principal Investigator: Daniel Lerman, MD, FACS         
Sinai Hospital of Baltimore Recruiting
Baltimore, Maryland, United States, 21215
Principal Investigator: Albert Aboulafia, MD, FACS         
Franklin Square Medical Center Recruiting
Baltimore, Maryland, United States, 21237
Principal Investigator: Albert Aboulafia, MD, FACS         
Johns Hopkins Hospital Recruiting
Baltimore, Maryland, United States, 21287
Principal Investigator: Carol Morris, MD, FACS         
United States, Massachusetts
Massachusetts General Hospital Recruiting
Boston, Massachusetts, United States, 02114
Principal Investigator: Joseph Schwab, MD, FACS         
Boston Children's Hospital Recruiting
Boston, Massachusetts, United States, 02115
Principal Investigator: Megan Anderson, MD, FACS         
Sub-Investigator: Mark Gebhardt, MD, FACS         
Beth Israel Deaconess Medical Center Recruiting
Boston, Massachusetts, United States, 02215
Principal Investigator: Megan Anderson, MD, FACS         
Sub-Investigator: Mark Gebhardt, MD, FACS         
United States, Minnesota
University of Minnesota Medical Center Recruiting
Minneapolis, Minnesota, United States, 55454
Principal Investigator: Edward Cheng, MD, FACS         
United States, New York
Albany Medical Center Recruiting
Albany, New York, United States, 11206
Principal Investigator: Matthew R DiCaprio, MD, FACS         
Maimonides Medical Center Withdrawn
Brooklyn, New York, United States, 11219
SUNY Upstate University Hospital Recruiting
East Syracuse, New York, United States, 13057
Principal Investigator: Timothy A Damron, MD, FACS         
Memorial Sloan-Kettering Cancer Center Recruiting
New York, New York, United States, 10065
Principal Investigator: John Healey, MD, FACS         
Long Island Jewish Medical Center | Northwell Health Not yet recruiting
Queens, New York, United States, 11040
Principal Investigator: Howard Goodman, MD, FACS         
Montefiore Medical Center Recruiting
The Bronx, New York, United States, 10467
Principal Investigator: David Geller, MD, FACS         
United States, Ohio
Wexner Medical Center Recruiting
Columbus, Ohio, United States, 43210
Principal Investigator: Thomas Scharschmidt, MD, FACS         
Sub-Investigator: Joel Mayerson, MD, FACS         
United States, Oregon
Oregon Health & Science University Hospital Recruiting
Portland, Oregon, United States, 97239
Principal Investigator: Yee-Cheen Doung, MD, FACS         
Sub-Investigator: James Hayden, MD, FACS         
United States, Pennsylvania
The Rothman Institute at Jefferson Recruiting
Philadelphia, Pennsylvania, United States, 19107
Principal Investigator: John Abraham, MD, FACS         
University of Pittsburgh Medical Center Recruiting
Pittsburgh, Pennsylvania, United States, 15213
Principal Investigator: Kurt Weiss, MD, FACS         
Sub-Investigator: Mark Goodman, MD, FACS         
United States, Tennessee
Vanderbilt Medical Center Recruiting
Nashville, Tennessee, United States, 37232-8774
Principal Investigator: Ginger Holt, MD, FACS         
Sub-Investigator: Herbert Schwartz, MD, FACS         
Sub-Investigator: Jennifer Halpern, MD, FACS         
United States, Utah
Huntsman Cancer Institute Recruiting
Salt Lake City, Utah, United States, 84112
Principal Investigator: Lor Randall, MD, FACS         
Sub-Investigator: Kevin Jones, MD, FACS         
United States, Wisconsin
Medical College of Wisconsin - Froedtert Hospital Recruiting
Milwaukee, Wisconsin, United States, 53226
Principal Investigator: John Neilson, MD, FACS         
Argentina
Hospital Universitario Austral Recruiting
Pilar, Buenos Aires, Argentina, 1629
Principal Investigator: Marcos Galli Serra, MD         
Sub-Investigator: Walter Parizzia, MD         
Australia, South Australia
Royal Adelaide Hospital Active, not recruiting
Adelaide, South Australia, Australia, 5000
Brazil
Instituto de Ortopedia e Traumatologia Recruiting
São Paulo, Brazil
Principal Investigator: André Mathias Baptista, MD         
Sub-Investigator: Juan Pablo Zumárraga, MD         
Canada, Alberta
Foothills Medical Centre Recruiting
Calgary, Alberta, Canada, T2N 5A1
Principal Investigator: Shannon KT Puloski, MD, FRCSC         
Sub-Investigator: Michael Monument, MD, FRCSC         
Canada, British Columbia
Vancouver General Hospital Recruiting
Vancouver, British Columbia, Canada, V5Z 4E6
Principal Investigator: Paul Clarkson, MD, FRCSC         
Canada, Ontario
Juravinski Hospital and Cancer Centre Recruiting
Hamilton, Ontario, Canada, L8V 5C2
Contact: Tricia Schneider, B.Sc    (905) 527-4322 ext 44983    schnep@mcmaster.ca   
Principal Investigator: Michelle Ghert, MD, FRCSC         
Sub-Investigator: Benjamin Deheshi, MD, FRCSC         
Ottawa Hospital Recruiting
Ottawa, Ontario, Canada, K1H 8L6
Principal Investigator: Joel Werier, MD, FRCSC         
Mount Sinai Hospital Recruiting
Toronto, Ontario, Canada, M5G 1X5
Principal Investigator: Peter Ferguson, MD, FRCSC         
Sub-Investigator: Jay Wunder, MD, FRCSC         
Canada, Quebec
Maisonneuve-Rosemont Hospital Recruiting
Montreal, Quebec, Canada, H1T4B3
Principal Investigator: Marc Isler, MD, FRCSC         
Sub-Investigator: Sophie Mottard, MD, FRCSC         
McGill University Health Centre Recruiting
Montreal, Quebec, Canada, H3G 1A4
Principal Investigator: Robert Turcotte, MD, FRCSC         
Hôtel-Dieu de Québec Recruiting
Québec City, Quebec, Canada, G1R 2J6
Principal Investigator: Norbert Dion, MD, FRCSC         
India
All India Institute of Medical Sciences Recruiting
New Delhi, Delhi, India
Principal Investigator: Shah Alam Khan, MBBS         
Sub-Investigator: Venkatesan Kumar, MBBS         
Netherlands
Leiden University Medical Center Recruiting
Leiden, South Holland, Netherlands, 2333
Principal Investigator: P.D. Sander Dijkstra, MD, PhD         
South Africa
Grey's Hospital Recruiting
Pietermaritzburg, South Africa
Principal Investigator: Reitze Rodseth, MBChB         
Sub-Investigator: Leonard Marais, MBChB         
Spain
Hospital Universitari Vall d'Hebron Recruiting
Barcelona, Spain, 08035
Principal Investigator: Roberto Vélez, MD         
Sponsors and Collaborators
McMaster University
Orthopedic Research and Education Foundation
The Physicians' Services Incorporated Foundation
Canadian Cancer Society Research Institute (CCSRI)
Canadian Institutes of Health Research (CIHR)
Investigators
Principal Investigator: Michelle Ghert, MD, FRCSC McMaster University
  More Information

Publications:
Responsible Party: Michelle Ghert, Professor | Department of Surgery, McMaster University
ClinicalTrials.gov Identifier: NCT01479283     History of Changes
Other Study ID Numbers: GHRT01
First Submitted: November 15, 2011
First Posted: November 24, 2011
Last Update Posted: May 25, 2017
Last Verified: May 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Keywords provided by Michelle Ghert, McMaster University:
Infection
Bone Neoplasms
Prosthesis
Anti-Bacterial Agents
Randomized

Additional relevant MeSH terms:
Bone Neoplasms
Neoplasms by Site
Neoplasms
Bone Diseases
Musculoskeletal Diseases
Anti-Bacterial Agents
Cefazolin
Antibiotics, Antitubercular
Anti-Infective Agents
Antitubercular Agents